![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1463653
À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : Áö¿ª ºÐ¼® - Á¦Ç°º°, ¼ö¼úº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(-2030³â)Europe Aortic Valve Replacement Devices Market Forecast to 2030 - Regional Analysis - by Product, Surgery, and End User . |
À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº 2022³â 18¾ï 1,209¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 44¾ï 7,602¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 12.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
³·Àº ħ½À ±â¼ú ¼ö¿ä Áõ°¡°¡ À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀ» µÞ¹Þħ
´ëµ¿¸ÆÆÇ¸· ġȯ¼ú¿¡¼ ³·Àº ħ½À ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÀÇ·á ÇàÀ§¿Í ȯÀÚ ¼±È£ÀÇ Å« º¯È¸¦ ¹Ý¿µÇÕ´Ï´Ù. ³·Àº ħ½À ´ëµ¿¸ÆÆÇ¸· ġȯ¼úÀº ¿òÁ÷ÀÓÀÌ ³ª»Û ´ëµ¿¸Æ ÆÇ¸·À» Àΰø ÆÇ¸·À¸·Î ´ëüÇÕ´Ï´Ù. ÀÌ Ãß¼¼ÀÇ ¹è°æÀº ¼ö¼úÀÇ Ä§½ÀÀ» ÃÖ¼ÒÈÇÏ°í °ü·Ã À§ÇèÀ» ÁÙÀ̰í ȸº¹ ½Ã°£À» ´ÜÃàÇÏ·Á´Â ¿å±¸¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. ³·Àº ħ½ÀÀû Á¢±Ù¹ýÀº ÀϹÝÀûÀ¸·Î Àý°³ âÀ» ÁÙÀÌ°í ½ÉÀå¿¡ Á¢±ÙÇϱâ À§ÇØ Æ¯¼ö µµ±¸¿Í ±â¼úÀ» »ç¿ëÇÕ´Ï´Ù. °Ô´Ù°¡ ȯÀÚÀÇ ÅëÁõµµ Àû°í ÀÏ»ó»ýȰ·ÎÀÇ º¹±Íµµ »¡¶óÁö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¿Ü°úÀÇ»ç´Â ÀáÀçÀûÀÎ ÀÌÁ¡À¸·ÎºÎÅÍ ÀÌ·¯ÇÑ ±â¼úÀ» ¹Þ¾ÆµéÀ̰í ÀÖÀ¸¸ç, ÀÇ·á±â±â¿Í ¼ö¼ú±â¼úÀÇ Áøº¸´Â ´õ¿í º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ÀÇ·á±â°üÀº ³·Àº ħ½À¼º ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ÀÇ·á ÆÀÀÇ ÈÆ·Ã ¹× ÇÊ¿äÇÑ ÀåºñÀÇ µµÀÔ¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ȯÀÚ¿¡°Ô Ä¡·á ¿É¼ÇÀÇ °³¼±°ú Àü¹ÝÀûÀÎ °Ç° Äɾî üÇèÀÇ Çâ»óÀ» Á¦°øÇÕ´Ï´Ù.
À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå °³¿ä
À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ½ÃÀåÀº µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ¿µ±¹, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ¼¼ºÐȵ˴ϴÙ. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀº ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõ ¹× ´ëµ¿¸Æ ÆÇ¸· Æó¼â ºÎÀüÁõ°ú °°Àº ÆÇ¸· º´ÁõÀÇ À¯º´·ü°úÀÌ Áö¿ªÀÇ ³·Àº ħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù.
À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(±Ý¾×)
À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå ¼¼ºÐÈ
À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº Á¦Ç°, ¼ö¼ú, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.
Á¦Ç°º°·Î, À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ¹«ºÀÇÕ ¹ëºê¿Í ±â°è½Ä ¹ëºê·Î ±¸ºÐµË´Ï´Ù. 2022³â À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ¹«ºÀÇÕ ¹ëºê°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¼ö¼ú¿¡ µû¶ó À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ³·Àº ħ½À ¼ö¼ú°ú °³º¹ ¼ö¼ú·Î ³ª´¹´Ï´Ù. ³·Àº ħ½À ¼ö¼ú ºÎ¹®Àº 2022³â¿¡ À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡¼ ´õ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2022³â À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå Á¡À¯À²¿¡¼ Ãִ븦 Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î º¼ ¶§ À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ¿µ±¹, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ºÐ·ùµË´Ï´Ù. µ¶ÀÏÀº 2022³â À¯·´ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Artivion Inc, JenaValve Technology Inc, Venus MedTech HangZhou Inc.
The Europe aortic valve replacement devices market is expected to grow from US$ 1,812.09 million in 2022 to US$ 4,476.02 million by 2030. It is estimated to grow at a CAGR of 12.0% from 2022 to 2030.
Increasing Demand for Minimally Invasive Techniques Fuels Europe Aortic Valve Replacement Devices Market
The increasing demand for minimally invasive techniques in aortic valve replacement surgeries reflects a significant shift in medical practice and patient preferences. In a minimally invasive aortic valve replacement, a poorly working aortic valve is replaced with an artificial valve. This trend is driven by the desire to minimize the invasiveness of procedures, reduce the associated risks, and promote faster recovery times. Minimally invasive approaches typically involve smaller incisions and the use of specialized instruments and technologies to access the heart, which can lead to shorter hospital stays and less scarring. Moreover, patients often experience less pain and a quicker return to their daily activities. Surgeons have embraced these techniques due to their potential benefits, and advancements in medical devices and surgical skills have further facilitated widespread adoption. As a result, healthcare institutions are investing in training their medical teams and acquiring the necessary equipment to meet the increasing demand for minimally invasive aortic valve replacement surgeries, thereby providing patients with improved treatment options and enhanced overall healthcare experiences.
Europe Aortic Valve Replacement Devices Market Overview
The Europe aortic valve replacement devices market is sub-segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. The regional market growth is associated with such as prevalence of valvular diseases, such as aortic stenosis & aortic regurgitation and others along with the increasing preference for minimally invasive surgeries in the region.
Europe Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Million)
Europe Aortic Valve Replacement Devices Market Segmentation
The Europe aortic valve replacement devices market is segmented into product, surgery, end user, and country.
Based on product, the Europe aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve held a larger Europe aortic valve replacement devices market share in 2022.
Based on surgery, the Europe aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held a larger Europe aortic valve replacement devices market share in 2022.
Based on end user, the Europe aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held the largest Europe aortic valve replacement devices market share in 2022.
Based on country, the Europe aortic valve replacement devices market has been categorized into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe aortic valve replacement devices market in 2022.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Artivion Inc, JenaValve Technology Inc, and Venus MedTech HangZhou Inc, are some of the leading companies operating in the Europe aortic valve replacement devices.